Abstract
Propofol total intravenous anesthesia is a common choice to anesthetize patients with increased intracranial pressure, reducing cerebral blood flow while maintaining cerebrovascular reactivity to CO2. Propofol and alfaxalone are commonly used for total intravenous anesthesia in dogs, but the effects of alfaxalone on cerebral blood flow and cerebrovascular reactivity to CO2 are unknown. Our hypothesis was that alfaxalone would not be significantly different to propofol, while isoflurane would increase cerebral blood flow and decrease cerebrovascular reactivity to CO2. Six healthy hound dogs were evaluated in this randomized crossover trial. Dogs were anesthetized with 7.5mg/kg propofol, 3mg/kg alfaxalone or 8% sevoflurane, mechanically ventilated and maintained with propofol (400µg/kg/min), alfaxalone (150µg/kg/min) or 1.7% end-tidal isoflurane, respectively, with one week washout between treatments. Cerebral blood flow and cerebrovascular reactivity to CO2 during hypercapnic and hypocapnic challenges were measured using arterial spin labelling and blood oxygen level-dependent magnetic resonance imaging sequences, respectively. Median (interquartile range, IQR) normocapnic cerebral blood flow was significantly lower (P=0.016) with alfaxalone compared to isoflurane, in the whole brain 15.39mL/min/100g (14.90-19.90mL/min/100g) vs. 34.10mL/min/100g (33.35-43.17mL/min/100g), the grey matter 14.57mL/min/100g (13.66-18.72mL/min/100g) vs. 32.37mL/min/100g (31.03-42.99mL/min/100g), the caudal brain 15.47mL/min/100g (13.37-21.45mL/min/100g) vs. 36.85mL/min/100g (32.50-47.18mL/min/100g) and the temporal lobe grey matter 18.80mL/min/100g (15.89-20.84mL/min/100g) vs. 43.32 (36.07-43.58mL/min/100g). Median (IQR) hypocapnic cerebrovascular reactivity to CO2 was significantly higher (P=0.016) for alfaxalone compared to isoflurane 8.85%S/mm Hg (6.92-10.44%S/mm Hg) vs. 3.90%S/mm Hg (3.80-4.33%S/mm Hg). Alfaxalone maintained lower cerebral blood flow and higher hypocapnic cerebrovascular reactivity to CO2 than isoflurane.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.